8 results on '"OVERALL survival"'
Search Results
2. Clinical Updates: KIDNEY CANCER. Updated data show OS benefit with adjuvant pembrolizumab in ccRCC.
3. Survival Outcomes and PROs Favor Cemiplimab + Chemotherapy vs Chemotherapy Alone in Advanced NSCLC Regardless of PD-L1 Status.
4. Induction Chemotherapy Prior to Chemoradiation Represents Potential New SOC in Locally Advanced Cervical Cancer.
5. Clinical Updates: BLADDER CANCER. Adding durvalumab to chemotherapy extends survival in MIBC.
6. Blue light cystoscopy decreases risk of recurrence, progression in NMIBC.
7. Pembrolizumab/axitinib sustains efficacy in ccRCC at 5-year follow-up.
8. Allogeneic Stem Cell Transplant Shows Minimal OS, PFS Benefits in Patients With MM.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.